Cross‐sectional study of plasma phosphorylated tau 217 in persons without dementia
Plasma phosphorylated tau 217 (p-tau217) is a promising biomarker of Alzheimer's disease (AD).We studied plasma p-tau217 in a population-based sample of 65- to -85-year-olds.We excluded those with a clinical diagnosis of AD.Older age and having an apolipoprotein E (<i>APOE</i>) ε4 allele were associated with higher plasma p-tau217.Heritability of p-tau217 was 56% and a genome-wide association study (GWAS) implicated genes around the <i>APOE</i> region.
Authors
- Jaakko A. Kaprio (ORCID: https://orcid.org/0000-0002-3716-2455)
- Eero Vuoksimaa (ORCID: https://orcid.org/0000-0002-6534-3667)
- Mia Urjansson
- Sari Kärkkäinen
- Valtteri Julkunen (ORCID: https://orcid.org/0000-0002-8727-8536)
- Teemu Palviainen (ORCID: https://orcid.org/0000-0002-7847-8384)
- Sanna‐Kaisa Herukka (ORCID: https://orcid.org/0000-0003-3308-8662)
- Tarja Kokkola (ORCID: https://orcid.org/0000-0002-3303-3912)
- Aino Aaltonen (ORCID: https://orcid.org/0009-0000-4543-8645)
- Toni Saari (ORCID: https://orcid.org/0000-0001-7721-3336)
- Mikko Hiltunen (ORCID: https://orcid.org/0000-0003-3566-4096)
- Aarno V. Palotie (ORCID: https://orcid.org/0000-0002-2527-5874)
- Heiko Runz (ORCID: https://orcid.org/0000-0002-2133-7345)
Institutions
- Broad Institute (US)
- University of Helsinki (FI)
- University of Eastern Finland (FI)
- Massachusetts General Hospital (US)
- Kuopio University Hospital (FI)
- Institute for Molecular Medicine Finland (FI)
- European Molecular Biology Laboratory (DE)
Publication Details
- Journal
- Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1002/dad2.70107
- Citations
- 6
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.99
Funders
- Boehringer Ingelheim
- Pfizer
- AstraZeneca
- Novartis
- Biogen
- Maze Therapeutics
- Academy of Finland
- Sigrid Juséliuksen Säätiö
- Business Finland
- Genentech